期刊文献+

玻璃体切除术联合视网膜激光光凝治疗严重增殖性糖尿病视网膜病变的疗效分析 被引量:2

Vitrectomy combined with photocoagulation of retina laser in treatment of severe proliferative diabetic retinopathy
下载PDF
导出
摘要 目的 :分析玻璃体切除术治疗严重增殖型糖尿病视网膜病变 (PDR)的疗效。 方法 :PDR患者 31例 (35眼 ) ,在控制血糖、血压情况下行玻璃体切除术 ,术中均作次全或全视网膜光凝。分析手术前后及随访 6~ 32个月的资料。结果 :最后随访时 ,视网膜平伏 ,眼底清晰可见 ,保留一定视力的手术成功眼为 2 9眼 ,最后成功率为 82 .9% ;病变较轻组比病变重度组成功率高 (P<0 .0 5 ) ;出血时间 >6个月组较出血时间≤ 6个月组成功率低 (P<0 .0 5 )。手术成功眼最后视力有明显提高 ,6 2 .9%达0 .1以上 ,2 8.6 %达 0 .4以上。 结论 :适时进行玻璃体切除术联合视网膜光凝治疗严重 Objective: To analyze the efficacy of vitrectomy treatment for severe proliferative diabetic retinopathy. Methods: To review and summarize the conditions of pre and post operation, as well as follow up in 31 cases. Results: At the end of the follow up study, the retina was flat, the least vision was retained, and the ocular fundus was clear in 29 eyes. The final success rate was 82.9%, higher in the group of less severe retinopathy than in the group of severe retinopathy ( P < 0.05), and lower in the group of vitreous hemorrhage > 6 months than in the group of vitreous hemorrhage ≤6 months ( P < 0.05). The final vision was significantly increased, better than 0.1 in 62.9%, better than 0.4 in 28.6%. Conclusion: Timely vitrectomy offers good therapeutic outcomes in the treatment of severe proliferative diabetic retinopathy. [
出处 《第二军医大学学报》 CAS CSCD 北大核心 2000年第12期1101-1103,共3页 Academic Journal of Second Military Medical University
基金 军队留学归国人员科研启动基金项目!(98H0 17)
关键词 糖尿病视网膜病变 玻璃体切除术 激光光凝术 diabetic retinopathy vitreous hemorrhage vitrectomy
  • 相关文献

参考文献2

二级参考文献2

共引文献18

同被引文献20

  • 1鲍炯琳,臧晶,朱宇东,林文雄.增殖性糖尿病视网膜病变的玻璃体切除术的疗效观察[J].中国眼耳鼻喉科杂志,2007,7(2):94-95. 被引量:11
  • 2Malone JI,Morrison AD,Pavan PR,et al. Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years'duration screened for the diabetes control and complications trial.Diabetes Care 2001;24(3):522-6.
  • 3Chaturvedi N, Sjoelie AK, Porta M, et al. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes.Diabetes Care 2001;24(2):284-9.
  • 4Kowluru RA, Engerman RL, Kern TS. Abnormalities of retinal metabolism in diabetes or experimental galactosemia Ⅷ.Prevention by aminoguanidine. Curr Eye Res 2000;21(4):814-9.
  • 5Nicolucci A,Carinci F,Graepel JG,et al. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data. Diabetes Care 1996;19(10):1091-6.
  • 6Xia P, Aiello LP, Ishii H, et al.Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C,its isoforms,and endothelial cell growth. J Clin Invest 1996;98(9):2018-26.
  • 7Nonaka A,Kiryu J, Tsujikawa A,et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats.Invest Ophthalmol Vis Sci 2000;41(9):2702-6.
  • 8Kunisaki M,Bursell SE,Clermont AC,et al.Vitamin E prevents diabetesinduced abnormal retinal blood flow via the diacylglycerol protein kinase C pathway.Am JPhysiol 1995;269(2 Pt 1):E239-46.
  • 9Bursell SE,Clermont AC,Aiello LP,et al.High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1diabetes.Diabetes Care 1999;22(8):1245-51.
  • 10Griggs J,Skepper JN,Smith GA,et al. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.Am J Pathol 2002;160(3):1097-103.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部